Study of Patients with Electrical Status Epilepticus in Sleep
NCT06792396
Recruiting
Our aims are: 1. To understand the diagnostic practices, treatment and long term management and outcomes for patients diagnosed with ESES locally. 2. To establish a regional and national guideline for the diagnosis and management of patients with ESES. The secondary questions that can be addressed with this case series review include the variability of clinical care given to patients with this condition, and for example, the duration of time it takes to obtain diagnostic tests and assessments... Read More
Gender:
ALL
Ages:
Between 1 year and 16 years
Trial Updated:
01/20/2025
Locations: East Suffolk and North Essex NHS Foundation Trust, Colchester, Not set
Conditions: Electrical Status Epilepticus in Sleep
Register for Updates
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
NCT05866627
Recruiting
The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/20/2025
Locations: Quotient Sciences, Nottingham, Nottinghamshire
Conditions: Healthy Volunteers
Register for Updates
Developing a Novel Therapy for Aversive Sensory Experiences in Autism
NCT06682858
Recruiting
The goal of this study is to assess whether a new psychological treatment can lead to changes in sensory experiences in autistic young people. Participants will complete a group intervention designed to help manage sensory difficulties and associated anxiety. Participants will also complete tasks before and after the intervention to assess whether the treatment can lead to changes in brain and behavioural responses to sensory experiences. The main questions the study aims to answer are: 1. Doe... Read More
Gender:
ALL
Ages:
Between 11 years and 16 years
Trial Updated:
01/20/2025
Locations: King's College London, London, Not set
Conditions: Autism, Autism in Children
Register for Updates
Biomarkers for Clinical Hypoxia Evaluation in Cervical Cancer
NCT05029258
Recruiting
Patients with locally advanced cervical cancer (LACC) are primarily treated with radiotherapy +/- chemotherapy however 5-year survival rates are \<60% with significant treatment toxicity. Hypoxia is a well-known radioresistant component of solid tumours such as cervical cancer and hypoxia modification therapies have demonstrated immense promise in treating such tumours. A major factor in determining a successful outcome with hypoxia modification is appropriate patient selection as it is hypoxic... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: The Christie NHS Foundation Trust, Manchester, Greater Manchester
Conditions: Cervical Cancer
Register for Updates
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320
Recruiting
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
01/17/2025
Locations: Phoenix Childrens Hospital, Phoenix, Arizona +95 locations
Conditions: Crohn's Disease (CD)
Register for Updates
Lung Innate Immunity and Microbiome After Tuberculosis Exposure
NCT06526689
Recruiting
To characterise the innate pulmonary immune response and respiratory microbiome after recent exposure to M.tb and to evaluate how differences determine the outcome of M.tb exposure
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/17/2025
Locations: Churchill Hospital, Oxford, Oxfordshire +2 locations
Conditions: Tuberculosis, Latent Tuberculosis
Register for Updates
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
NCT06630260
Recruiting
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended Phase 2 dose (RP2D). In the Phase 1b of this study parallel biomarker defined arms will be opened, initially in the relapsed GMB setting, enrolling 12 patients onto each arm. These patients will be treated with avutometinib and defactinib double therapy. Avutometinib will be... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
01/17/2025
Locations: Cambridge University Hospitals, Cambridge, Not set +2 locations
Conditions: Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT06346067
Recruiting
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2025
Locations: Mayo Clinic - Arizona, Phoenix, Arizona +58 locations
Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Register for Updates
Neuropsychiatric Research Databases for People With Intellectual Disabilities and Epilepsy (REFINE)
NCT06780501
Recruiting
This study consists of two parts: Part One: De-identified Database The goal of this part is to establish a research database containing de-identified data about People with Intellectual Disabilities (PwID) and epilepsy, collected from three NHS sites across England and Wales. Researchers will gather information from participants' medical records, including clinical details, epilepsy history, and medications, and will enter this data into a secure database where all identifying details are remo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Cornwall Partnership NHS Foundation Trust, Bodmin, Not set +2 locations
Conditions: Epilepsy, Intellectual Disability, Learning Disability
Register for Updates
Implementing an Intervention Named Volitional Help Sheets to Reduce Smoking Behaviour Among Young Adults in Indonesia
NCT05629039
Recruiting
Indonesia is one of the countries that does not sign The World Health Organization Framework Convention on Tobacco Control (WHO-FCTC), and the numbers of Indonesian smokers increase every year. The Volitional-Help Sheet (VHS) has been used successfully to help people quit smoking, but has not yet been tested in Indonesia. The present study aims to adapt and implement the VHS to promote smoking cessation among smokers aged 20- 45 years. The main outcome measure is smoking abstinence; secondary ou... Read More
Gender:
ALL
Ages:
Between 20 years and 45 years
Trial Updated:
01/16/2025
Locations: Rina Rahmatika, Manchester, Not set
Conditions: Smoking Cessation
Register for Updates
A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)
NCT06412250
Recruiting
The objective of this post marketing observational registry is to evaluate clinical outcomes (safety and performance) in an all-comers population with coronary artery disease (CAD) treated with the Polymer Free Sirolimus Eluting Coronary Stent Vivo ISAR and planned for an abbreviated (≤ 3 months) dual antiplatelet therapy (DAPT) regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Zydus Hospitals, Ahmedabad, Not set +26 locations
Conditions: Cardiovascular Diseases
Register for Updates
Investigation of Three Biomarkers for the Detection of Prostate Cancer
NCT06554587
Recruiting
GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies. The purpose of this study is to further evaluate the sensitivity and specificity of the GlycoScore biomarkers for the detection of clinically significant prostate cancer. Sensitivity and specificity will be determined for each marker, combinations of the three markers and combinations of the GlycoScore bi... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/16/2025
Locations: Royal Liverpool University Hospital, Liverpool, Not set
Conditions: Cancer of Prostate
Register for Updates